27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- European Medicines Agency's Committee for Medicinal Products for Human Use recommended approving Takeda Pharmaceutical Co Ltd's (NYSE:TAK) dengue vaccine candidate, TAK-003.
- In August, Indonesia approved Takeda's dengue vaccine, Qdenga, for individuals six to 45 years.
- The recommendation covers the dengue vaccine candidate to prevent dengue disease caused by any serotype in individuals four years of age and older in Europe and dengue-endemic countries.
- The Committee's positive opinion was supported by results across five Phase 1, 2, and 3 trials with over 28,000 participants.
- This includes four and a half years of follow-up data from the global, pivotal Phase 3 TIDES trial, consistent with the World Health Organization's recommendation to obtain three to five years of follow-up data after completing a primary dengue vaccination to assess safety and efficacy accurately.
- TIDES exploratory analyses showed that throughout the four and a half years of study follow-up, TAK-003 prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases in the overall population.
- TAK-003 has been generally well tolerated, with no evidence of disease enhancement in vaccine recipients.
- Price Action: TAK shares are up 0.31% at $12.92 on the last check Friday.
- Photo by Himas Rafeek from Pixabay
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!